Long Acting Therapy to Improve Treatment SUccess in Daily LifE (The LATITUDE Study)

Long Acting Therapy to Improve Treatment SUccess in Daily LifE (The LATITUDE Study)
Recruiting
18 years - 70 years
All
Phase 3
640 participants needed
1 Location

Brief description of study

This study is meant for patients who have difficulty taking their HIV meds as prescribed.  One goal of the study is to test the effectiveness of long-acting antiretroviral therapy (ART) -- a once-a-month injection that replaces daily ART pills. You will also receive compensation for participating in this study, with additional compensation based on your medication adherence.

Detailed description of study

Study Activities and Length:

The study will last up to 180 weeks (three and a half years) and is broken into four "steps." Steps 1-3 involve active participation and Step 4 is for long-term follow-up and observation. 

Step 1: The first part of the study lasts up to 24 weeks and involves taking your once-a-day pills as best you can. If you keep your viral load undetectable during this step, you'll be paid a bonus and move onto Step 2.
 
Step 2: If you are eligible and wish to continue onto Step 2,  you will be randomly assigned to receive either pills or injections. Once you complete Step 2 and if you decide to continue on-study, you are guaranteed to start injections in Step 3. 

Step 3: You will receive two ART injections each month in the clinic and will come in for visits to have your health monitored. Once you complete Step 3, if you decide to continue on ART injections, the study is complete. 

Step 4: is only for people who want to return to taking pills after injections, and involves coming back for regular follow-up visits. 

Requirements for Participation:  

Note: The following requirements are some but not all requirements for participation. Full eligibility details may be discussed directly with study staff.

Inclusion:
  • Diagnosis of HIV
  • Evidence of non-adherence to ART 
  • If a person of child-bearing potential, a willingness to use contraception for the duration of the study
Exclusion:
  • Unwillingness to receive injections
  • Currently pregnant or planning to become pregnant
  • Certain seizure disorders
  • Advanced liver disease
  • History of or current active hepatitis B infection
  • Current or anticipated use for chronic anti-coagulation therapy

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Antiretroviral Therapy,HIV infection
  • Age: 18 years - 70 years
  • Gender: All

Note: The following requirements are some but not all requirements for participation. Full eligibility details may be discussed directly with study staff.

Inclusion:
  • Diagnosis of HIV
  • Evidence of non-adherence to ART 
  • If a person of child-bearing potential, a willingness to use contraception for the duration of the study
Exclusion:
  • Unwillingness to receive injections
  • Currently pregnant or planning to become pregnant
  • Certain seizure disorders
  • Advanced liver disease
  • History of or current active hepatitis B infection
  • Current or anticipated use for chronic anti-coagulation therapy

Updated on 04 Aug 2024. Study ID: 844630

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center